- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for Santarus Inc (SNTS)
| Open: | 21.3000 | Day's Range: | 21.2800 - 21.9700 | Volume: | 1,054,755 |
|---|---|---|---|---|---|
| Previous Close: | 21.2700 | 52wk Range: | 4.8201 - 21.9700 | 1-Yr Rtn: | +288.48% |
Key Statistics for SNTS
| Current P/E Ratio (ttm) | 42.7096 |
|---|---|
| Estimated P/E(12/2013) | 23.8152 |
| Relative P/E vs. SPX | 2.6176 |
| Earnings Per Share (USD) (ttm) | 0.5130 |
| Est. EPS (USD) (12/2013) | 0.9200 |
| Est. PEG Ratio | 1.2758 |
| Market Cap (M USD) | 1,416.05 |
| Shares Outstanding (M) | 64.63 |
| 30 Day Average Volume | 1,336,992 |
| Price/Book (mrq) | 13.2268 |
| Price/Sale (ttm) | 5.5168 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for SNTS
Company Profile & Key Executives for SNTS
Santarus Inc. is a pharmaceutical company focused on acquiring, developing and commercializing proprietary products for patients treated by gastroenterologists and other physicians. The company currently markets products for the treatment of upper GI diseases and disorders and type 2 diabetes, and is developing drugs for the treatment of lower GI disorders.
| Gerald T ProehlPresident/CEO | Wendell D WierengaExec VP:Research & Dev |
| Debra P CrawfordSenior VP/CFO/Treasurer/Secy | William C Denby IIISenior VP:Commercial Ops |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
SNTS News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page